106 related articles for article (PubMed ID: 27532673)
1. Poor Prognosis Associated with High Levels of Thymidine Phosphorylase and Thrombocytosis in Patients with Renal Cell Carcinoma.
Huang X; Wang L; Chen Y; Zheng X; Wang X
Urol Int; 2017; 98(2):162-168. PubMed ID: 27532673
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of TP/PD-ECGF and thrombocytosis in gastric carcinoma.
Wang L; Huang X; Chen Y; Jin X; Li Q; Yi TN
Eur J Surg Oncol; 2012 Jul; 38(7):568-73. PubMed ID: 22595739
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of platelet count in patients with renal cell carcinoma.
Erdemir F; Kilciler M; Bedir S; Ozgok Y; Coban H; Erten K
Urol Int; 2007; 79(2):111-6. PubMed ID: 17851278
[TBL] [Abstract][Full Text] [Related]
4. Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma.
Shimada H; Oohira G; Okazumi S; Matsubara H; Nabeya Y; Hayashi H; Takeda A; Gunji Y; Ochiai T
J Am Coll Surg; 2004 May; 198(5):737-41. PubMed ID: 15110807
[TBL] [Abstract][Full Text] [Related]
5. Quantitative analysis of thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma.
Morita T; Matsuzaki A; Tokue A
Oncology; 2003; 65(2):125-31. PubMed ID: 12931018
[TBL] [Abstract][Full Text] [Related]
6. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma.
Ito K; Asano T; Yoshii H; Satoh A; Sumitomo M; Hayakawa M
Int J Urol; 2006 Nov; 13(11):1365-70. PubMed ID: 17083384
[TBL] [Abstract][Full Text] [Related]
7. Thrombocytosis and hematocrit as prognostic factors in renal carcinoma.
Seda CJ; Salas AS; Sánchez CG; Blasco JM; García IO; Sánchez JM; Ruíz CB; Navarro SM; López RA
Arch Esp Urol; 2011 Nov; 64(9):883-90. PubMed ID: 22155876
[TBL] [Abstract][Full Text] [Related]
8. The significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor activity in renal cell carcinoma.
Mizutani Y; Wada H; Yoshida O; Fukushima M; Kawauchi A; Nakao M; Miki T
Cancer; 2003 Aug; 98(4):730-6. PubMed ID: 12910516
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of thrombocytosis in renal cell carcinoma patients.
Inoue K; Kohashikawa K; Suzuki S; Shimada M; Yoshida H
Int J Urol; 2004 Jun; 11(6):364-7. PubMed ID: 15157203
[TBL] [Abstract][Full Text] [Related]
10. Significance of thrombocytosis for determining prognosis in patients with localized renal cell carcinoma.
Göğüş C; Baltaci S; Filiz E; Elhan A; Bedük Y
Urology; 2004 Mar; 63(3):447-50. PubMed ID: 15028435
[TBL] [Abstract][Full Text] [Related]
11. High levels of thymidine phosphorylase as an independent prognostic factor in renal cell carcinoma.
Takayama T; Mugiya S; Sugiyama T; Aoki T; Furuse H; Liu H; Hirano Y; Kai F; Ushiyama T; Ozono S
Jpn J Clin Oncol; 2006 Sep; 36(9):564-9. PubMed ID: 16861722
[TBL] [Abstract][Full Text] [Related]
12. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma.
Imazano Y; Takebayashi Y; Nishiyama K; Akiba S; Miyadera K; Yamada Y; Akiyama S; Ohi Y
J Clin Oncol; 1997 Jul; 15(7):2570-8. PubMed ID: 9215827
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of thrombocytosis in renal cell carcinoma.
Bensalah K; Leray E; Fergelot P; Rioux-Leclercq N; Tostain J; Guillé F; Patard JJ
J Urol; 2006 Mar; 175(3 Pt 1):859-63. PubMed ID: 16469566
[TBL] [Abstract][Full Text] [Related]
14. Thymidine phosphorylase as a prognostic factor in renal cell carcinoma.
Padrik P; Saar H
Int Urol Nephrol; 2010 Jun; 42(2):295-8. PubMed ID: 19572207
[TBL] [Abstract][Full Text] [Related]
15. Thymidine phosphorylase levels as a prognostic factor in renal cell carcinoma.
Wada S; Yoshimura R; Naganuma T; Yoshida N; Narita K; Ikemoto S
BJU Int; 2003 Jan; 91(1):105-8. PubMed ID: 12614261
[TBL] [Abstract][Full Text] [Related]
16. Role of preoperative platelet level in clinical and pathological outcomes after surgery for renal cortical malignancies.
Wosnitzer M; Polland A; Hai Q; Hruby G; McKiernan J
BJU Int; 2011 Jul; 108(1):73-9. PubMed ID: 21166746
[TBL] [Abstract][Full Text] [Related]
17. [Expression and clinical significance of thymidine phosphorylase/platelet-derived endothelial cell growth factor in renal cell carcinoma].
Huang X; Wang L; Shi HB; Zhang XJ; Men XW; Chen B; Wang XH
Zhonghua Yi Xue Za Zhi; 2011 Nov; 91(44):3127-30. PubMed ID: 22340655
[TBL] [Abstract][Full Text] [Related]
18. Thrombocytosis as a prognostic factor in patients with renal cell carcinoma: a meta-analysis of literature.
Men H; Liang C; Yu M
J Cancer Res Ther; 2015; 11(1):67-72. PubMed ID: 25879339
[TBL] [Abstract][Full Text] [Related]
19. Thymidine phosphorylase/platelet-derived endothelial cell growth factor (PD-ECGF) associated with prognosis in renal cell carcinoma.
Suzuki K; Morita T; Hashimoto S; Tokue A
Urol Res; 2001 Feb; 29(1):7-12. PubMed ID: 11310220
[TBL] [Abstract][Full Text] [Related]
20. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma.
Suppiah R; Shaheen PE; Elson P; Misbah SA; Wood L; Motzer RJ; Negrier S; Andresen SW; Bukowski RM
Cancer; 2006 Oct; 107(8):1793-800. PubMed ID: 16983701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
